vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and EverQuote, Inc. (EVER). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $190.9M, roughly 1.3× EverQuote, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 9.8%, a 1.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 14.5%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 27.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
EverQuote, Inc. is an online insurance marketplace founded in 2011 and based in Cambridge, Massachusetts.
ANIP vs EVER — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $190.9M |
| Net Profit | $27.5M | $18.7M |
| Gross Margin | — | 97.8% |
| Operating Margin | 14.1% | 12.3% |
| Net Margin | 11.1% | 9.8% |
| Revenue YoY | 29.6% | 14.5% |
| Net Profit YoY | 367.5% | 133.7% |
| EPS (diluted) | $1.14 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $190.9M | ||
| Q4 25 | $247.1M | $195.3M | ||
| Q3 25 | $227.8M | $173.9M | ||
| Q2 25 | $211.4M | $156.6M | ||
| Q1 25 | $197.1M | $166.6M | ||
| Q4 24 | $190.6M | $147.5M | ||
| Q3 24 | $148.3M | $144.5M | ||
| Q2 24 | $138.0M | $117.1M |
| Q1 26 | — | $18.7M | ||
| Q4 25 | $27.5M | $57.8M | ||
| Q3 25 | $26.6M | $18.9M | ||
| Q2 25 | $8.5M | $14.7M | ||
| Q1 25 | $15.7M | $8.0M | ||
| Q4 24 | $-10.3M | $12.3M | ||
| Q3 24 | $-24.2M | $11.6M | ||
| Q2 24 | $-2.3M | $6.4M |
| Q1 26 | — | 97.8% | ||
| Q4 25 | — | 97.7% | ||
| Q3 25 | — | 97.3% | ||
| Q2 25 | — | 96.9% | ||
| Q1 25 | — | 96.8% | ||
| Q4 24 | — | 96.3% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 95.7% |
| Q1 26 | — | 12.3% | ||
| Q4 25 | 14.1% | 9.5% | ||
| Q3 25 | 15.9% | 10.1% | ||
| Q2 25 | 6.6% | 9.0% | ||
| Q1 25 | 13.3% | 4.8% | ||
| Q4 24 | -2.3% | 8.2% | ||
| Q3 24 | -13.8% | 8.1% | ||
| Q2 24 | 3.7% | 5.4% |
| Q1 26 | — | 9.8% | ||
| Q4 25 | 11.1% | 29.6% | ||
| Q3 25 | 11.7% | 10.8% | ||
| Q2 25 | 4.0% | 9.4% | ||
| Q1 25 | 8.0% | 4.8% | ||
| Q4 24 | -5.4% | 8.3% | ||
| Q3 24 | -16.3% | 8.0% | ||
| Q2 24 | -1.7% | 5.5% |
| Q1 26 | — | $0.51 | ||
| Q4 25 | $1.14 | $1.53 | ||
| Q3 25 | $1.13 | $0.50 | ||
| Q2 25 | $0.36 | $0.39 | ||
| Q1 25 | $0.69 | $0.21 | ||
| Q4 24 | $-0.45 | $0.35 | ||
| Q3 24 | $-1.27 | $0.31 | ||
| Q2 24 | $-0.14 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $178.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $240.9M |
| Total Assets | $1.4B | $324.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $178.5M | ||
| Q4 25 | $285.6M | $171.4M | ||
| Q3 25 | $262.6M | $145.8M | ||
| Q2 25 | $217.8M | $148.2M | ||
| Q1 25 | $149.8M | $125.0M | ||
| Q4 24 | $144.9M | $102.1M | ||
| Q3 24 | $145.0M | $82.8M | ||
| Q2 24 | $240.1M | $60.9M |
| Q1 26 | — | $240.9M | ||
| Q4 25 | $540.7M | $238.0M | ||
| Q3 25 | $505.8M | $174.9M | ||
| Q2 25 | $436.8M | $170.3M | ||
| Q1 25 | $418.6M | $149.5M | ||
| Q4 24 | $403.7M | $135.4M | ||
| Q3 24 | $405.9M | $117.7M | ||
| Q2 24 | $455.8M | $100.8M |
| Q1 26 | — | $324.0M | ||
| Q4 25 | $1.4B | $326.9M | ||
| Q3 25 | $1.4B | $256.1M | ||
| Q2 25 | $1.3B | $241.4M | ||
| Q1 25 | $1.3B | $232.1M | ||
| Q4 24 | $1.3B | $210.5M | ||
| Q3 24 | $1.3B | $180.5M | ||
| Q2 24 | $920.8M | $158.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $29.6M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 1.59× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $29.6M | ||
| Q4 25 | $30.4M | $27.0M | ||
| Q3 25 | $44.1M | $19.8M | ||
| Q2 25 | $75.8M | $25.3M | ||
| Q1 25 | $35.0M | $23.3M | ||
| Q4 24 | $15.9M | $20.1M | ||
| Q3 24 | $12.5M | $23.6M | ||
| Q2 24 | $17.4M | $12.4M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $25.8M | ||
| Q3 25 | $38.0M | $18.5M | ||
| Q2 25 | $71.8M | $23.8M | ||
| Q1 25 | $32.5M | $22.2M | ||
| Q4 24 | $13.5M | $19.1M | ||
| Q3 24 | $7.7M | $22.1M | ||
| Q2 24 | $13.0M | $11.5M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 13.2% | ||
| Q3 25 | 16.7% | 10.6% | ||
| Q2 25 | 34.0% | 15.2% | ||
| Q1 25 | 16.5% | 13.3% | ||
| Q4 24 | 7.1% | 13.0% | ||
| Q3 24 | 5.2% | 15.3% | ||
| Q2 24 | 9.4% | 9.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.6% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 0.7% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.2% | 1.0% | ||
| Q2 24 | 3.2% | 0.7% |
| Q1 26 | — | 1.59× | ||
| Q4 25 | 1.10× | 0.47× | ||
| Q3 25 | 1.66× | 1.05× | ||
| Q2 25 | 8.87× | 1.72× | ||
| Q1 25 | 2.23× | 2.92× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
EVER
| Automotive | $172.4M | 90% |
| Home and renters | $18.5M | 10% |
